tiprankstipranks
Advertisement
Advertisement
Soligenix reports Q1 EPS (28c) vs. (97c) last year
PremiumThe FlySoligenix reports Q1 EPS (28c) vs. (97c) last year
2M ago
Soligenix price target lowered to $1.50 from $10 at Alliance Global
Premium
The Fly
Soligenix price target lowered to $1.50 from $10 at Alliance Global
2M ago
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
Premium
The Fly
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
2M ago
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
PremiumTipRanks NewswireSoligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
3M ago
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
Premium
The Fly
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
3M ago
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
3M ago
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
PremiumTipRanks NewswireSoligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
3M ago
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
3M ago
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100